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ABSTRACT
PREPARATION OF NANOVEHICLES FOR TARGETED DRUG DELIVERY
By
Anagha Avinash Bhakay
Application of nanotechnology in pharmaceutical research has opened new frontiers for
drug development and its efficient delivery. In recent years, the focus of the research
has been on the engineering of nano/micro-particulate structures for efficient and
targeted delivery of drugs for selective and enhanced absorption. This work throws light
on the preparation of biodegradable and non-toxic nanoparticulate systems for targeted
drug delivery. The drug vehicles were made by two different processes namely
electrostatic interactions and desolvation process. The drug carriers made by these
processes were found to be in the size range of 150-200nm which is necessary for
cellular uptake of the drug carriers. The albumin nanocarriers were modified by
antibody and showed binding to the Ramos lymphoma cells in-vitro.
Formation of nano-sized Active Pharmaceutical Ingredient (API) particles is
another application of nanotechnology, where small size leads to improved solubility.
Hence the API size reduction by milling was carried out to increase the bioavailability
of the APIs after their incorporation in different dosage forms. The stable aqueous
suspensions of the API were obtained using polymers and surfactants which could be
mixed with excipients and formulated into thin film strips.
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CHAPTER 1
INTRODUCTION
1.1 Background
Drug delivery is the method or process of administering a pharmaceutical compound to
achieve a therapeutic effect in humans or animals. They are the means of administering
drugs to the body in a safe, efficient, reproducible and convenient manner. They modify
the drug release profile, absorption, distribution and elimination for the benefit of
improving product efficacy, safety, patient convenience and compliance. They also
protect therapeutic agents from degradation in the biological system.'
Most common routes of drug delivery include the oral (through the mouth),
topical (skin), transmucosal (nasal, buccal/sublingual, vaginal, ocular and rectal),
inhalational and parenteral (intravenous, intramuscular, subcutaneous). 2 Oral dosage
forms like tablets, capsules, syrups, suspensions are the most preferred formulations.
However many medications such as proteins, antibodies, vaccines, gene based drugs
cannot be delivered orally because they might be susceptible to enzymatic degradation or
cannot be absorbed efficiently into the systemic circulation due to their molecular size,
charge issues and chemical nature. Apart from advances in formulation development,
protect therapeutic agents from degradation in the biological system.' efforts are being
made in the development of new drugs using combinatorial chemistry, drug modeling to
prepare drugs that selectively bind to certain receptors in the body. 3 Also despite of
advances in the development of new drugs, a drug may never reach the target organ, or it
may be difficult to achieve the necessary level of drug in the body. Large doses can result
1
2in serious side effects and can harm normal cells and organs, and for this reason there is a
need to develop controlled release formulations and targeted drug delivery systems. 4
During the past three decades, formulations that control the rate and period of
drug delivery (i.e., time-release medications) and target specific areas of the body for
treatment have become increasingly common and complex. Because of the ever-evolving
understanding of the human body and the explosion of new and potential treatments
resulting from discoveries of bioactive molecules and gene therapies, pharmaceutical
research hangs on the precipice of yet another great advancement. However, this next
leap poses questions and challenges to not only the development of new treatments but
also the mechanisms with which to administer them.
The current methods of drug delivery exhibit specific problems like drug
potencies and its therapeutic effects which are limited or otherwise reduced because of
the partial degradation that occurs before they reach a desired target in the body. Also
certain time-release medications, after ingestion, deliver treatment continuously, rather
than providing relief of symptoms and protection from adverse events. However, this
improvement cannot happen until methods are developed to safely shepherd drugs
through specific areas of the body, such as the stomach, where low pH can destroy a
medication, or through an area where healthy bone and tissue might be adversely
affected. 5 Hence current efforts in the area of drug delivery include the development of
targeted delivery in which the therapeutic molecule is only active in the target area of the
body, for example, in cancerous tissues. Drug delivery to the targeted areas of the body
prevents' side effects caused by chemotherapeutic agents and thereby protects the healthy
tissue. Dose of the drug administered can also be reduced since drug release occurs at the
3required site, causing reduction in the drug loss by absorption, distribution, metabolism
and excretion (ADME) and thus increasing the bioavailability.
1.2 Problem Definition
There are different types of delivery systems like polymeric micelles, liposomes,
nanosomes and dendrimers which are being used for targeted delivery. 6 Most of these
systems make use of polymers, strong organic solvents and complex reaction systems.
The basic problem faced in such systems is the toxicity of organic solvents which
compromises the biocompatibility of the final formulation. To circumvent these problems
water-soluble, biodegradable, polymeric nanoparticles, derived from polysaccharides
proteins, polyelectrolytes were developed as drug carriers.' These systems find
application in treatment of diseases like cancer.
All the dosage forms incorporate active pharmaceutical ingredients (API). The
pharmacokinetic and pharmacodynamic of API depends on its chemical nature, particle
size, partition coefficient, lypophilic/hydrophilic, amorphous/crystalline nature and the
presence of functional groups. Almost 40-70 % of APIs are hydrophobic and have low
water solubility which limits their bioavailability. Therefore, particle size also plays a
crucial role in the solubility and stability of the dosage forms. Micronization of such APIs
increases interfacial surface area and hence increases the solubility and bioavailability.
Also lower the particle size, easier it is for the API to enter the cells and cause a
therapeutic effect. Particle size reduction of APIs thus becomes one of the most important
unit operations in the process of manufacturing of pharmaceutical dosage forms. An
attempt has been made to resolve these issues in this work.
41.3 Objective
The objective of the study was preparation, characterization, crosslinking and conjugation
of biodegradable nanocarriers for targeted drug delivery. The aim was to obtain stable
suspensions with nanoparticle size < 200 nm for cellular uptake. The conjugated antibody
was to carry the nanocarriers to specific cells for the drug release from the carrier and
cause a therapeutic effect. The particle size of APIs had to be reduced to < 1 um and
overcome the problem of particle agglomeration for their incorporation in thin film strips.
1.4 Scope and Organization of Thesis
The work revolves completely around particle formation processes for drug delivery. It
includes the preparation of drug delivery vehicles for parenteral administration and
micronization of APIs for the development of oral/inhalational dosage forms. The
parenteral formulation systems can be prepared in the form of microemulsions and
colloidal systems for intravenous administration; biodegradable fibers and fibrin-gels for
intramuscular/subcutaneous administration. For the oral dosage forms the particles after
micronization can be made available as dry powders, suspensions, emulsions to be
incorporated in tablets, gels and syrups. The particles have to be in dry powder form for
their incorporation in metered dose/powder inhalers and as liposomes for nebulisers. In
the current work the drug delivery vehicles were made in the form of nanoparticles for
parenteral route of administration and as suspensions for the thin film strips.
The processes of particle formation, the current methods in use and the
contributions made by this work have been discussed in the following chapters. This
study begins with an overview of different drug delivery systems. The second chapter
5reviews the polyelectrolyte and albumin nanoparticles, their method of preparation and
targeted drug delivery. Also it reviews the different processes of particle size reduction of
APIs and the process of milling in particular. The chapter 3 consists of experimental
work that includes parametric study, particle characterization and in-vitro studies. It is
followed by the results and discussions and conclusions in chapters 4 and 5, respectively.
CHAPTER 2
NANOPARTICLES FOR DRUG DELIVERY- A REVIEW
2.1 Introduction
Research into the rational delivery and administration of pharmaceutical, therapeutic and
diagnostic agents is at the forefront of the pharmaceutical industry. The range of
bioactive substances emerging as potential drug candidates, together with those currently
under research and development, continue to provide major challenges for efficient drug
delivery and targeting. The important task of the drug delivery system is to provide a
defined dose, at a chosen rate, at a selected time, to a targeted biological site. Key issues
in the design of delivery systems include use of materials that are not toxic, compatible
with other excipients, target specific, achieve regulatory approval and clearance and also
handle the constraints imposed by the nature of the various routes of administration.
A large number of delivery systems have been made using polymers,
polysaccharides, proteins. Therapeutic and diagnostic agents can be encapsulated,
covalently attached or adsorbed on to such nanocarriers. The nanoparticulate carriers can
be surface modified with synthetic polymers and appropriate ligands; they can be targeted
to specific cells and locations within the body after parenteral routes of administration. 7
These approaches can overcome drug toxicity issues. Some nanocarriers are being
designed with the focus on multifunctionality that is these carriers can target cell
receptors and simultaneously deliver drugs and biological sensors. But some carriers have
poor drug loading capacity. If the drug loading capacity of the carrier is low, the drug
used should be highly potent and also have a small particle size. 7 There are various
6
7approaches like liquid anti-solvent, desolvation process, rapid expansion of supercritical
solutions, jet milling, spray drying and ball milling used for particle size reduction of
active pharmaceutical ingredients. 8 The scale-up of some of these approaches becomes
difficult. Hence, milling continues to be the most commonly used method. The drug
substances are milled in millers and the smaller particles are then stabilized with the use
of surfactants, polymers and stabilizers. These processes form particles in size ranges that
are suitable for incorporation in different delivery platforms. The reduced particle size
has high surface area and hence, a strategy for faster drug absorption and therapeutic
effect.
2.2 Limitations and Opportunities for Targeting
The fate of drugs after administration depends on several processes: distribution,
metabolism and excretion when given by the parenteral route whereas absorption,
distribution, metabolism and excretion when administered by the oral delivery. When
injected intravenously the particles are cleared rapidly from the circulation by the liver
cells (Kupffer cells) and the spleen macrophages. Opsonization, which is surface
deposition of blood opsonic factors such as fibronectin, immunoglobulin and complement
proteins, often aid particle recognition by these macrophages. 9 Larger particles (200 nm
and above) efficiently activate the human complement system and hence are cleared
faster from the blood by Kupffer cells. ¹0 The binding of blood proteins and opsonins to
nanoparticles depends on the surface properties such as the presence of certain functional
groups and surface charge density. 9 ' ¹¹ ' ¹2
8It is necessary to overcome these limitations for efficient therapeutic delivery. The
distribution of drug at the required tissue is important for which there is a need of locally
acting carrier since the drug exposure to the biological environment might inactivate it by
the mechanisms described above. Suppression of opsonization events is also important
for enhancing the passive retention of nanoparticles at sites and compartments other than
macrophages in contact with the blood and is a reflection of long circulatory profile of
such surface manipulated nanoparticles. 9 Apart from surface engineering, now there are
novel materials like synthetic polymers, polymer-conjugates and block copolymers that
can form sterically stabilized nanostructures with macrophage evading properties. ¹3
Drug incorporation into delivery systems offers many advantages like enhancing
the therapeutic potential of drugs, alteration of pharmacokinetics, biodistribution and
sustained release, drug stabilization, reduction of systemic drug toxicity, decreased
dosing frequency, patient compliance and effective accumulation in the targeted site.
Also the carrier system should be non-toxic, biocompatible and compatible with the
incorporated drug, preserve the drug activity and deliver the drug at the required site with
reproducible pharmacodynamics.
2.3 Nanoparticles as Delivery Vehicles
Nanoparticles are structures that range from 1 to 1000nm and their preferred size is < 300
nm for cellular uptake. They can be used as carriers for drugs, DNA, peptides and
genes. ¹4 Polymer-based nanoparticle systems can be made from different processes like
emulsion, dispersion and inverse microemulsion polymerization and may involve use of
9toxic organic solvents in the preparation process which compromises the biocompatibility
of the formulation.
Water soluble, biodegradable, polymeric, polyelectrolyte nanoparticles were
developed to overcome the use of toxic solvents. They degrade at a slow rate, do not alter
normal cell function and use water as the solvent. Polyelectrolyte complex dispersions
are formed by strong electrostatic interaction between at least two oppositely charged
polyelectrolytes. Protein-based nanoparticles can be prepared by emulsion formation,
desolvation or coacervation processes. ¹5 Both the systems are biocompatible, non-toxic
and have a high drug loading capacity and hence can be used as carriers for targeted
delivery.
2.4 Polyelectrolyte Complex Nanoparticles 7 ' ¹6
The polyions of opposite charges interact electrostatically with each other to form
polyelectrolyte complex (PEC) nanoparticles. Hydrogen bonding, hydrophobic
interactions and van der Waals forces complement PEC formation. ¹7 Two major steps
involved in PEC formation:
• Kinetic diffusion process of mutual entanglement between polymers which
depends on molar size differences
• Thermodynamic rearrangement of already formed aggregates due to
conformational changes and disentanglement
Different types of aqueous PECs that have been prepared: ¹8
• Soluble PEC, i.e., macroscopically homogenous systems containing small PEC
aggregates
• Turbid colloidal, PEC systems in the transition range to phase separation
(a) (b)
e Two phase system of supernatant liquid and precipitated PEC, which are readily
separated as a solid
Two structural models for PECs that are described in the literature are dependant on the
polyion groups, stoichiometry and molecular weight:
o The ladder-like structure where complex formation takes place on a molecular
level via conformational adaptation
• The scrambled egg model where a large number of chains are incorporated into
the particle architecture 19
Figure 2.1 schematic representations of (a) ladder-like structure and (b) scrambled egg
structure. Black represents polyanion and gray represents polycation. 16
The ladder-like structure consists of hydrophilic single stranded and hydrophobic
double stranded segments. These phenomena result from mixing of polyelectrolytes
having weak ionic groups and large differences in molecular dimensions and can result
into water-soluble and insoluble PECs. The scrambled egg structures are a product of
polyions with strong ionic groups and comparable molar masses yielding insoluble and
highly aggregated complexes. The stoichiometry is adjusted under dilute conditions. The
colloidal PECs contain a neutral core surrounded by excess binding polyelectrolytes
which stabilize the particles against agglomeration. 20 The surplus cation bound to a
neutral anionic core leads to stability by repulsion between similarly charged particles
11
and vice versa in case of surplus anion bound to a neutral cationic core. The steps
involved in the formation of both ladder-like and scrambled egg assemblies are the same
but they only result in desired structures under certain conditions.
2.4.1 Biological Interactions of PECs
The size of PECs is critical in cell binding and internalization. It has been demonstrated
that 100 nm NPs exhibited a 2.5-fold greater uptake relative to 1 1.1,m particles and they
had a 6 fold greater uptake relative to 10 µm particles.²¹ In addition to the size, surface
charge on the PEC nanoparticles also controls their binding. The surface charge also
controls the particle stability in aqueous liquid suspension by the electrostatic forces
exerted by the particle surfaces.
Cellular surfaces are dominated by negatively charged sulfated proteoglycans,
molecules that play pivotal roles in cellular proliferation, migration, and motility. Cell
surface proteoglycans consist of a core protein anchored to the membrane and linked to
one or more glycosaminoglycan side chains (heparan, dermatan, keratan or chondroitin
sulfates) to produce a structure that extends away from the cell surface.
Glycosaminoglycans are highly anionic, and the interactions between proteoglycans and
NP shells, if positively charged, tend to be largely ionic. Hence the polycationic PEC
nanoparticles have advantage of cell binding and also particle stability.? Once inside the
cell, degradation of polymers may occur, but targeting specific intracellular organelles is
possible depending on the surface charge and attached ligands.²2
12
2.4.2 Modes of PEC Internalization
The PEC nanoparticles are taken up by the cells by endocytosis. Endocytosis results in
internalization of the cell's plasma membrane to form vesicles that capture
macromolecules and particles present in the extracellular fluid and/or bound to
membrane-associated receptors. The internalized cargo is then directed to appropriate
intracellular compartment. Endocytosis takes place by fluid-phase pinocytosis, adsorption
and receptor mediated. The bulk uptake of solutes in the exact proportion to their
concentration in the extracellular fluid occurs in fluid-phase pinocytosis whereas during
adsorptive and receptor mediated endocytosis macromolecules are bound to the cell
surface and concentrated before internalization. 7 ' ¹6
It has been described in the literature that PEC internalization is through
macropinocytosis. In the absence of a targeting ligand cationic PECs bind cells through
electrostatic interactions where cells serve as the anionic sink to mediate the
attachment. ²3
2.5 Protein Nanoparticles
Protein-based drug delivery can potentially result in high intratumor drug concentration,
ease of administration and shorter infusion times. ¹5 Protein nanoparticles can be made
from bovine serum albumin, human serum albumin etc.
Albumin nanoparticles are versatile protein carriers for drug targeting and
improving the pharmacokinetic profile of peptide or protein based drugs. Albumin is the
most abundant plasma protein (35-50 g/L human serum) with a molecular weight of 66.5
kDa. It is synthesized in the liver where it is produced at a rate of approximately 0.7 mg/h
13
for every gram of liver (i.e. 10-15 g daily); Human serum albumin (HSA) exhibits an
average half-life of 19 days. The functions and binding properties of HSA are multifold:
a) it binds a great number of therapeutic drugs such as penicillin, sulfonamides, indole
compounds, and benzodiazepines; b) it is the major protein responsible for the colloid
osmotic pressure of the blood; c) when HSA is broken down, the amino acids provide
nutrition to peripheral tissue. ²4
Figure 2.2 X-ray structure of human serum albumin.
The three-dimensional structure of HSA can be described as an ellipsoid
consisting of three flexible spheres in a row (domains I, II, III) and is illustrated
schematically. HSA is one of the smallest proteins present in blood plasma. Both size and
abundance help the transport of large number of metabolic compounds and therapeutic
drugs. The binding sites for metabolic substrates and diagnostic as well as therapeutic
drugs have been shown in the Figure 2.2.
Albumin is an acidic, very soluble protein that is extremely robust: it is stable in
the pH range of 4-9. These properties as well as its preferential uptake in tumor and
14
inflamed tissue, its ready availability, its biodegradability, its non-antigenicity and its
lack of toxicity and immunogenicity make it an ideal candidate for drug delivery. ²4
2.5.1 Mode of Internalization of Albumin NPs
As given in the literature the HSA nanoparticles are mostly distributed into the primary
human macrophages into non-nucleic intracellular compartments. Albumin accumulates
in malignant and inflamed tissue due to a leaky capillary combined with an absent or
defective lymphatic drainage system. It has been demonstrated that tumors are able to
trap plasma proteins and utilize their degradation products for proliferation. Albumin is
found to be a major energy and nutrition source for tumor growth. ²4
Albumin is thought to facilitate endothelial transcytosis of unbound and albumin-
bound plasma constituents into extravascular space. This process is initiated by binding
of albumin to a cell surface, 60-kDa glycoprotein (gp60) receptor (albondin), which in
turn results in binding of gp60 with an intracellular protein (caveolin-1) and subsequent
invagination of the cell membrane to form transcytotic vesicles, referred to as caveolae.¹ 5
Albumin reversibly binds to a number of hydrophobic substances and allows their
transport in the body and release at the cell surface. Albumin NPs can thus be used as
drug delivery vehicles.
2.6 Targeted Drug Delivery
The nanoparticles act as delivery vehicles for therapeutic agents to prevent the side
effects of the drug, protect the healthy tissue, promote sustained release and reduce the
dose of the drug. Targeting therapeutics to specific sites in the body will increase the
15
efficacy of drugs while reducing the dose required along with negative side effects. The
delivery of drugs to hard to reach places, such as the brain or cancerous tissues, may also
be possible.
The polymeric nanoparticles are conjugated to different ligands like poly-ethylene
glycol, peptides, and antibodies for targeting the drug vehicles to selected extracellular
and intracellular targets. Among these targeting moieties antibodies have the advantage
of high specificity but they are expensive, time-consuming to produce and have problems
with stability and storage. Non-antibody ligands suffer from lower selectivity and affinity
but they are inexpensive and easy to handle. ?
Antibodies are well-established systems to target the colloidal carriers to specific
cell types. This principal is based on defined receptor ligand interaction which enables
the surface binding and cellular internalization of drug carriers conjugated to the
antibody. Also the antibody has to be chemically modified to enable the conjugation with
drug carrier. The surface of the drug carrier also needs to be modified for conjugation.
The drug carriers are crosslinked and the crosslinker is then conjugated with the
chemically modified antibody. Thus the antibody carries the drug carrier to the specific
sites. A variety of antibodies can be used depending on the receptors present on the
cells.²5 Cancer cells often over express receptors for peptides which provide an
opportunity for the active and specific targeting of the drug carriers to cancerous tissues.
Thus the nanoparticle system loaded with an anticancer drug and conjugated with an
antibody can be used for cancer therapy while reducing the side effects and increasing the
effectivity of the drug.
16
2.7 API Micronization
The drug can be loaded into the core of nanoparticles or adsorbed onto their surface. The
particle size of the API needs to be reduced to increase the surface area of absorption and
enhance the effect of drug. Two different approaches namely top-down and bottom-up
approach can be used to obtain particles in the nano-size range for drug delivery. In the
top down approach the larger particles are broken down to nano-size range. In the
bottom-up approach the particles are built up from molecules. 8
2.7.1 Top-Down Approach
Comminuting or grinding or milling is the oldest mechanical unit operation for size
reduction of APIs and for producing large quantities of particulate materials. The material
is subjected to stress which results in breakage of particles. With decreasing particle size,
materials exhibit increasing plastic behavior making it more difficult to break the small
particles. A limit in grindability can be reached where further grinding does not decrease
the particle size. 26 Most of the pharmaceutical size reduction operations utilize the high-
shear wet milling for the production of NPs. The API being milled needs to be stable
during the entire process of milling. Also care needs to be taken because of the
contamination due to milling.
Figure 2.3 Schematic diagram of top-down approach.
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2.7.2 Bottom-up Approach
In this process the drug is dissolved in a solvent, the nanoparticles are then precipitated
by removing the solvent rapidly or by mixing an antisolvent to the solution, reducing its
solubilizing strength. Initially the nuclei are formed which grow because of condensation
and coagulation giving the final particles. If the rate of desolubilization is slow then the
sticky nuclei particles are formed that have a higher tendency to agglomerate giving
large-size final particles. Based on these requirements two general methods for
nanoparticle production are used namely supercritical fluid process ²7 and emulsification-
diffusion process. The key aspect of getting nanoparticles of the desired size is to control
the particle coagulation. 8
Figure 2.4 Schematic diagram of bottom-up approach.
2.8 API Micronization by Milling
In the case of bottom-up technologies one starts with the molecules in solution and moves
via association of these molecules to the formation of solid particles. The disadvantage of
this technology is the use of solvents creates additional costs and increases the number of
manufacturing steps. Also the prerequisite of this process is the drug has to be soluble in
one solvent and this solvent has to be miscible with the nonsolvent. Many of the drug
compounds are poorly soluble in aqueous and simultaneously in non-aqueous media, thus
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excluding this formulation approach. ²8
 Hence the top-down technology is preferred. They
can be categorized into pearl/ball milling and high pressure homogenization.
Micronization of drug powders by colloid mills or jet mills are of limited use
since they lead to particles in the size range of 0.1 and 20 urn. It has been shown that drug
nanosuspensions can be obtained by running a pearl mill over a sufficiently long period
of time. These mills consist of a milling container filled with milling pearls or balls. The
container can be static and the milling material is moved by means of a stirrer;
alternatively the complete container is moved in a complex movement leading to
movement of milling pearls. A problem associated with this technology is the erosion
from milling material during the milling process. The extent of erosion depends on the
solid concentration of the macrosuspension to be processed, the hardness of the drug and
the required milling time and milling material. 8
 The erosion of the material from the
container also may occur. Normally the product containers are made of steel (SS 316) to
solve the problem of container material erosion and maintain the required quality
specifications of the formulation.
The nano/micro suspensions are stabilized by the addition of stabilizers and
surfactants. ²9
 The coarse drug powder is dispersed by high speed stirring in a
surfactant/stabilizer solution to yield a microsuspension. The choice of surfactants and
stabilizers depends on the properties of drug (affinity to surfactant/stabilizer), physical
principles (electrostatic/steric stabilization) and the route of administration. Electrolytes
reduce the zeta potential and thus impair the physical stability of the suspension. The
optimal approach is use a combination of steric stabilizer for steric stability and ionic
surfactant for electrostatic stabilization. For oral administration there is a wide choice of
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charged surfactants, however for parenteral route it is limited e.g. for intravenous
injection poloxamer 188, lecithin, tween 80, sodium glycocholate, polyvinyl pyrrolidone
are accepted. Production of nanosuspensions of the drug for parenteral route has to be
done in sterile conditions and the product has to be pyrogen free. Also in case of pearl
mills the product needs to be separated from the milling pearls at the end of the milling
process.8 Apart from pearl/ball mills, other grinding mills like Micros can be used. The
milling material is attached to a central shaft which rotates vigorously and helps breaking
of particles. Milling material consists of ceramic rings attached to sub shafts. The
separation step of milling material from the product is reduced in this case.
2.9 Remarks based on Literature Review
2.9.1 Preparation of Nanoparticles for Targeted Delivery
The polyelectrolyte complex nanoparticles are made from water-soluble and
biodegradable polymers. They are biocompatible and stable. The structure of PEC
nanoparticles is available in the literature but there is a need to understand the mechanism
of formation of the particles. The process of formation of the nanoparticles needs to be
optimized to get the particles in a reproducible manner. The nanoparticles can be targeted
by conjugation with various ligands like peptides and polyethylene glycol. The amine
groups on the PEC NPs can also be modified by crosslinking with SMCC by an amide
linkage and then conjugated with a thiolated antibody.
The albumin nanoparticles are non-antigenic, have a number of binding sites and
made of amino acids which indicate the presence of a large number of amine groups that
are required for conjugation. Albumin nanoparticles can be prepared reproducibly by the
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desolvation process as available in the literature. They have been efficiently conjugated
with antibody for drug delivery. A different antibody could be conjugated with the
albumin nanoparticles to target different cells in the body to study the cell binding and
internalization of the nanoparticles.
2.9.2 Preparation of Nanosuspensions of APIs by Milling
It has been discussed in the literature that there is a need for nanosize APIs for their quick
absorption and efficient therapeutic effect. Milling has been the most commonly used
method for API size reduction. The ball/pearl mills are commonly used for wet milling.
However wet milling can be done in Micros since it has an advantage that the milling
material is not mixed with the product as is the case with ball/pearl mills. Micros thus
reduces one step of separation of milling material from the product in the process of
manufacturing.
As given in the literature the API suspensions can be stabilized with a variety of
surfactants and stabilizers to prevent particle agglomeration and coagulation and yield
stable suspensions in a reproducible manner. The particle size of a large number of APIs
have been reduced by wet milling. However particle size reduction of drugs like
griseofulvin (an antifungal agent), by the process of wet milling using Micros still needs
to be tried.
CHAPTER 3
EXPERIMENTAL SECTION
3.1 Nanoparticles for Parenteral Drug Delivery
Two different nanovehicles were prepared namely polyelectrolyte complex nanoparticles
and albumin nanoparticles. In this chapter materials and methods used in this work have
been discussed.
3.1.1 Polyelectrolyte Complex Nanoparticles
Materials
Polyanion: Sodium alginate was obtained from Vanderbilt University at Nashville,
Tennessee and chondroitin sulfate from Sigma Aldrich.
Polycation: Spermine tetrahydrochloride was obtained from Sigma Aldrich and
Polymethylene (-co-guanidine) hydrochloride (PMCG) was ordered from Polymeric
Products Inc.
Pluronic F-68 and Calcium chloride were obtained from Sigma Aldrich.
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Figure 3.1 Structures of polymethylene (co-guanidine) hydrochloride, spermine
tetrahydrochloride, sodium alginate and chondroitin sulfate.
Experimental Section
Figure 3.2 Experimental set-up (top), polycation (bottom left) and polyelectrolyte
nanoparticles (bottom right).
23
Method of Preparation
The solution of polyanions sodium alginate (0.5mg/ml) and chondroitin sulfate
(0.5mg/ml) in distilled water were taken in the burette. The solution of polycations
PMCG (0.5mg/ml) and spermine tetrahydrochloride (0.5mg/ml) were taken in a glass
beaker. The Pluronic F-68 (1mg/ml) and Calcium Chloride (0.5mg/ml) were dissolved in
the cationic solution. The cationic solution was kept under continuous magnetic stirring
at room temperature. The polyanion solution was added to the polycationic solution at a
rate of 1ml/min. The polyelectrolyte nanoparticles were obtained instantaneously. The
nanoparticles were separated from the solution by centrifugation at a speed of 10,000 rpm
(13900g) (in Sorvall centrifuge) at 4° C for 10 minutes. After centrifugation the
nanoparticles were resuspended to its original volume with 10mM sodium acetate buffer
pH 4.2. The nanoparticles were washed three times to remove the excess polycations and
stabilizer. ²³ The particles were characterized by particle size measurements using N4
plus, particle images by Scanning Electron Microscopy (SEM) and the amine group
determination by Fluorescence Microplate Reader. ³°
3.1.2 Albumin Nanoparticles
Materials
Human serum albumin (Fraction V powder), sodium chloride, ethanol (USP) and 8%
aqueous solution of glutaraldehyde were obtained from Sigma Aldrich.
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Method of Preparation
The experimental set-up was the same as the polyelectrolyte complex nanoparticles. The
200 mg Human Serum Albumin was dissolved in 2 ml 10 mM sodium chloride solution.
The pH of the solution was adjusted to 9.0 using 10mM sodium hydroxide solution. ³2 The
albumin solution was kept under continuous magnetic stirring. 8 ml ethanol solution was
added through the burette at a rate of 1ml/min to the albumin solution at room
temperature. After complete addition of ethanol the particles were crosslinked by the
addition of 235 ill 8% aqueous glutaraldehyde solution. The particles were then separated
from the solution by centrifugation at 11,500 rpm (16,100 g) (in Sorvall centrifuge) at
15°C for 8 minutes. ³¹ The albumin nanoparticles were washed three times and after every
wash they were resuspended to the original volume with 10mM sodium chloride solution
pH 9.0.³² The particles size measurements were done by N4 plus, images were taken by
Scanning Electron Microscopy and amine group determination by Fluorescence
Microplate Reader.
3.1.3 Particle Size Measurement
The nanoparticle solution (3 ml) was taken in a cuvette and particle size was measured at
angles of 23°, 43.6°, 60° and 90° using N4 Plus by the Photon Correlation Spectroscopy
(PCS). A drop of the NP solution was placed on the SEM stub for SEM micrographs.
The stub was coated with carbon to prevent degradation of sample due to charging.
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3.1.4 Amine Group Determination
The amine groups available on the surface of nanoparticles were measured by the
reaction with fluorescamine. 10 µl of the sample was added to 140 µl 40mM PBS buffer
pH 7.4 taken in the well of fluorescence microplate reader. 40 of fluorescamine
(3mg/ml) solution was pipetted into this well. The fluorescence was measured at an
excitation wavelength of 400 nm and emission of 460 nm. ³° A calibration curve was
plotted for solutions with known amount of amine groups and the amine groups of the
unknown solutions were calculated from the calibration curve.
3.1.5 Crosslinking and Conjugation
After the surface available amines were determined, the crosslinking and conjugation
were done at the Center for Molecular Medicine and Immunology (CMMI), Belleville,
NJ. The nanoparticle solution was divided into two parts A (1 ml) and B (7 ml). SMCC
was not added to solution A and it was retained as a control sample. 128 µ,1 of SMCC
solution (6mg/ml in water) was added to solution B and was magnetically stirred for 45
minutes for crosslinking. The excess SMCC was removed by three steps of centrifugation
at 16,000 g at 15°C for 8 min (in Beckman Coulter JA 17 rotor) and after every wash the
sample was resuspended to the original volume with 10mM sodium chloride solution pH
7.4. After the last wash the particles were resuspended in acetate buffer (pH 6.0) for
antibody conjugation. Solution A also underwent centrifugation since it was retained as
control. The solution B was then split into two parts (3.5 ml each), one part received the
800 pi (1.53 mg/ml) antibody and the other was retained as control. The Fab' -SH was
stirred with NP-sufo-SMCC for 45 minutes. ²5 The Fab'-NP conjugate was purified by
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three centrifugation steps (16,000g, 8 min) and redispersion of pellet to original volume
in sodium chloride pH 7.4. The particle size of these samples was measured by N4 plus
and the in-vitro studies were performed by Fluorescence Assisted Cell Sorting
(FACScan) ³³ at CMMI.
3.2 API Size Reduction for Oral Drug Delivery
Materials
Griseofulvin, Hydroxypropylmethyl cellulose (HPMC), Polymer JR, Polyvinyl
Pyrrolidone (PVP), Sodium Alginate (SA) and Pluronic F-68 were obtained from Sigma
Aldrich.
Griseofulvin with molecular formula C17H17O6 is an antibiotic with antifungal
properties. It is derived from a species of Penicillium. It is used in the treatment of
ringworm and other fungal infections of the skin or nails.
Figure 3.3 Structure of Griseofulvin.
The polymers and surfactants were used for stabilization of the particle size. The
structures of the polymers are given below.
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Figure 3.4 Structures of sodium alginate, PEG, Pluronic, HPMC, PVP and Polymer JR.
Experimental Set-up
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Figure 3.5 Construction of micros.
The vessel of Micros is made of stainless steel and has a capacity of 400 ml. The
grinding parts consist of ceramic rings arranged on sub-shafts and the sub-shafts in turn
revolve around a central main shaft (planetary motion) which has an impeller at the
bottom. The grinding takes place due to the shear forces between the rings and the wall of
the vessel and in-between the rings. Cooling water is passed continuously through the
jacket to maintain a constant temperature.
Method
The polymer/surfactant solutions at concentrations of l, 5, 10 wt% of the drug were
prepared. The polymers used were sodium alginate, polymer JR, polyethylene glycol,
pluronic F-68 and polyvinyl pyrrolidone. 2.0 Wt % of griseofulvin was suspended in the
above solutions. The 350 ml sample was loaded in the Micros vessel and cooling water
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was passed through the jacket to maintain a constant temperature at 24°C. The suspension
was milled at 1500 rpm for 75 minutes. The suspension was then unloaded from Micros
and taken for particle size measurement.
Particle Size Measurement
The particle size was measured by light scattering (Beckman Coulter LS 230). The
Polarization Intensity Diffraction Scattering (PIDS) was performed. The SEM images
were taken by placing a drop of the sample on the SEM stub and the sample was coated
with carbon to prevent the charging of the sample.
CHAPTER 4
RESULTS AND DISCUSSION
4.1 Polyelectrolyte Complex Nanoparticles
The particle size of the polyelectrolyte complex nanoparticles depends on the pH, charge
ratio, stoichiometry of the ions, 19 molecular weight, stirring speed, concentration of
stabilizer³4 and calcium chloride. Hence the process of preparation of polyelectrolyte
complex nanoparticles was optimized by variations in the above parameters to get stable
nanoparticles.
4.1.1 Effect of Charge Ratio
The charge ratios were varied knowing the molecular weights and charge on each
polymer unit.
Figure 4.1 Effect of charge ratio on particle size of the PEC nanoparticles.
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Figure 4.2 SEM Micrographs of PEC nanoparticles at charge ratios 0.52 and 11.7.
The particle size of the PEC nanoparticles increased with increase in charge ratio.
The excess positive charge on the particles promoted the repulsion between the particles
and hence stabilized the particles. At low charge ratios there was no excess charge on the
particles and hence they agglomerated as seen in the SEM micrographs.
4.1.2 Effect of pH
The effect of pH on the particle size was studied in two ways:
• Change in pH of polycation solution (Before Centrifugation)
• Change in pH after particle separation (After Centrifugation)
4.1.2.1 Before Centrifugation. 	 The pH of the polycationic solution was varied by
the addition of Hydrochloric acid for acidic pH and Sodium hydroxide for basic pH.
Figure 4.3 Variation in particle size with change in pH before centrifugation.
At acidic pH excess of protons were present in the solution. As per the Le
Chateliers principle the equilibrium shifted to the left, the nanoparticles do not dissociate
and the excess positive charge was retained on the particles leading to small particle size.
At basic pH excess hydroxide ions were present. To maintain equilibrium the
nanoparticles dissociated loosing their excess positive charge and hence increase in
particle size was observed.
4.1.2.2 After Centrifugation.
	 The particles were separated by centrifugation and
resuspended in sodium acetate buffer for acidic pH and phosphate buffer for basic pH.
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Figure 4.4 Change in particle size with variation in pH after centrifugation.
Figure 4.3 showed a clear tendency towards aggregation as pH approached
neutrality corresponding to change in surface charge. As the pH increased from 3 to 7,
the particle size increased rapidly due to decrease in the repulsive surface charges. Also
the particle size stabilized after increasing the pH above 7.6. This type of behavior on
either side of neutrality indicated that PEC nanoparticles exhibit Zwitterionic behavior.
At low pH the carboxyl and amino groups were in the protonated state indicating excess
positive surface charge. As the pH increases to 7, the amino and carboxyl groups
dissociated depleting the surface charge leading to the coalescence of the particles. 16 As
pH was increased above 7.6, the carboxyl anions were formed, thus retaining an excess
negative charge and leading to a stable particle size.
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4.1.3 Effect of Stabilizer Concentration
The stoichiometry of polycations and polyanions and the pH was kept constant. The
concentration of Pluronic F-68 was increased from 0 to 10mg/ml to study its effect on
particle size.
Figure 4.5 Change in particle size of PEC NPs with increase in stabilizer concentration.
A slight dip in particle size was observed with increase in pluronic concentration
from 0 to 1 mg/ml and the particle size increased after pluronic concentration of 2 mg/ml.
The surfactant stabilized the PEC NPs by forming a coat on the particle surface, thus
preventing particle agglomeration. However the critical micellar concentration of
Pluronic F-68 is l.8 mg/ml. Beyond the CMC the surfactant formed reverse micelles and
lost its tendency to protect the particles from coalescence. Hence the increase in particle
size was observed.
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4.1.4 Effect of Electrolyte Concentration
The concentrations of polyanion, polycation and stabilizer and the pH were kept constant.
The concentration of Calcium Chloride was varied to study its effect on particle size.
Figure 4.6 Change in particle size with variation in electrolyte concentration.
The particle size was found to increase with increase in the electrolyte
concentration. The chloride ions reacted with the amine groups on the particle surface or
were adsorbed on the surface. It reduced the surface charge on the particles and hence the
particles coalesce leading to larger particle size. ³5
 The calcium chloride was used to
enhance the electrostatic interaction between the polyelectrolytes and it played a role of
maintaining an electrolyte balance inside the body.
4.1.5 Effect of Mixing Speed
The polycation solution was kept under continuous magnetic stirring during the particle
formation process. The stirring speed was varied to optimize the speed that can be used to
get nanoparticles in a reproducible manner. The concentration of polyelectrolytes,
stabilizer, salt and pH were kept constant to study the effect of mixing speed.
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Figure 4.7 Variation of particle size with stirring speed.
Figure 4.7 indicated a decrease in particle size initially with an increase in the
mixing speed (using a VWR stirrer). However, the particle size increases at higher
speeds. At low speed, the mixing was not sufficient and the particles tend to coalesce to
form larger particles. At higher speeds, the mixing was vigorous and the frequency of
particle collisions increased resulting in an increase in particle size. Thus it was observed
that the optimum speed was crucial for sufficient mixing and lower particle size.
4.1.6 Effect of Centrifugation on Particle Size
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Figure 4.8 Bar graph showing increase in PEC particle size after centrifugation (top) and
SEM micrographs of PEC particles before (bottom left) and after centrifugation (bottom
right).
The particle size of PEC NPs increased after centrifugation due to agglomeration
between the particles caused by the increased collisions during centrifugation and
removal of excess positive charge. The size increased to 450-500 nm and hence the
particles could not be used for cellular uptake studies.
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The optimized parameters were as given below:
• Charge ratio of polycation : polyanion was 25: 1
• Pluronic F-68 concentration: 1 mg/ml
• Use of calcium chloride was avoided since it causes an increase in particle
size.
• Resuspension buffer was 10 mM sodium acetate buffer pH 4.2
o Mixing speed was fixed at 2800 rpm
4.1.6 Amine Group Determination
The amount of amine groups available for crosslinking was determined by reaction with
Figure 4.9 Calibration curve for amine group determination.
PMCG was dissolved in water to make a series of solutions at concentrations of
0.l, 0.2, 0.3, 0.5, 5 and 10 mg/ml. 10 p.l of each sample was pipetted into 140 1.11 of the
PBS buffer pH 7.4 taken in the fluorescence microplate reader. 50 µl of the fluorescamine
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solution 3 mg/ml in acetone was pipetted into each of the sample and the fluorescence
was determined. The moles of amine in the polyelectrolyte nanoparticles were calculated
from the number of amine groups on PMCG.
The number of surface amines on the PEC NPs was found to be 9.75 X 10
-11
moles. From the fluorescence readings it was clear that most of the PMCG remains
unreacted since the supernatant solution obtained after centrifugation gave a higher
reading. The amines available on the surface of PEC NPs were insufficient for
crosslinking. So the PEC NPs could not be conjugated for targeted delivery. Hence a
different system of nanoparticles was chosen for drug delivery.
4.2 Albumin Nanoparticles
The optimized procedure for making the albumin nanoparticles was obtained from
literature. The particle size and amine groups of the albumin nanoparticles were
determined.
The amine count of albumin nanoparticles was 1.678 X 10 -9 moles which was
feasible for crosslinking with SMCC. The complex of albumin nanoparticles and SMCC
was conjugated with antibody for drug delivery as shown in the schematic diagram.
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Figure 4.10 Schematic diagram of antibody conjugation.
The particle size of the albumin nanoparticles at different stages are given below:
Table 4.1 Mean Particle Size of Albumin Nanoparticles at Different Stages
41
Figure 4.11 SEM micrographs of albumin nanoparticles after preparation (top) and after
conjugation (bottom).
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The particle size of the nanoparticles was acceptable for cellular uptake. The in-vitro
studies of the nanoparticles were done by Fluorescence Assisted Cell Sorting (FACScan).
The FACScan images shown below clearly indicate nanoparticle binding to the
lymphoma cells. The Figure 4.12 serves as a control. In the Figures 4.13 and 4.14, the
indirect staining method was used. In this method the antibody that binds to the surface of
the cell is not fluoresceinated and it binds to a second step fluoresceinated FITC-Ab
reagent specific for the determinants on the non-fluorescent first-step antibody. Hence the
stain amplifies because several molecules of second-step FITC-Ab bind to one molecule
of first-step reagent. The cell count decreased because the size of the Fab'-NP conjugate
was larger and hence bound to fewer cells.
Figure 4.12 FACScan image showing FITC-Ab + Ramos cells.
Figure 4.14 FACScan image of Ramos cells + Fab'-NP + FITC-Ab.
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4.3 API Size Reduction
4.3.1 Optimization of Process Parameters*
The milling conditions that are the time of milling, optimum speed of milling and the
concentration of the sample to be used were optimized in NJCEP laboratory. The
optimized conditions have been shown below.
Figure 4.15 Plot showing the effect of concentration of the drug sample (top) and milling
time (bottom) on the mean particle size of drug.
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The particle size of griseofulvin decreased initially with increase in concentration
because of the shear stress acting on the particles. However at higher concentration
particle agglomeration dominated over the shear stress and hence there was an increase in
particle size. Similarly when the time of milling was increased, the residence time for the
growth of particles increased and hence the increase in size was observed.
Figure 4.16 Plot showing the effect of milling speed on the mean particle size of the
drug.
The particle size of griseofulvin decreased initially with an increase in the milling
speed due to the increase in shear stress acting on the particles. At higher speeds the
particle collisions increased that lead to a slight increase in the particle size due to
agglomeration.
These optimized process parameters were used to stabilize the API suspensions
by co-milling using different surfactants and polymers. The effects of these materials
have been discussed below.
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4.3.2 Co-milling with Polymers
Hydroxypropyl methyl cellulose (HPMC), sodium alginate, polymer JR, polyethylene
glycol (PEG) and polyvinyl pyrrolidone (PVP) were used to control the particle size of
the API suspensions. The concentrations of the polymers are with respect to the drug.
Figure 4.17 Plot showing the effect of varying concentrations of HPMC and sodium
alginate on the particle size of griseofulvin.
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The particle size was reduced by milling. In the absence of polymer/stabilizer the particle
size was not stable since the particles agglomerated. HPMC and sodium alginate formed
a coat around the drug particles and hence protected direct interaction between the drug
particles, thereby preventing agglomeration.
Figure 4.18 Plot of cumulative volume percent versus particle size for Polymer JR.
Figure 4.19 Plot of cumulative volume percent versus particle size for polyethylene
glycol.
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Figure 4.20 Plot of cumulative volume percent versus particle size for polyvinyl
pyrrolidone.
Figures 4.18, 4.19 and 4.20 indicated that there was no change in particle size
with the increasing polymer concentration. The polymer JR, PEG and PVP might not be
wetting the drug particles and hence the particles could not be prevented from
agglomeration.
4.3.3 Co-milling with Surfactants
Sodium dodecyl sulfate (SDS) and Pluronic F-68 were used to prevent particle
agglomeration. The concentrations of the surfactants used have been calculated with
respect to the drug concentration.
Figure 4.21 Plot showing the effect of SDS on particle size.
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Figure 4.22 Plot of cumulative volume percent versus particle size for Pluronic F-68.
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Signal A = InLens
Pixel Size = 13.2 nm
Figure 4.23 SEM Micrographs of the griseofulvin particles before milling (top) and after
milling with sodium alginate (bottom).
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Figure 4.24 SEM Micrographs showing griseofulvin after milling with SDS (top) and
Pluronic (bottom).
Figure 4.25 Plot showing the mean particle size of griseofulvin after co-milling with
polymers/surfactants at different concentrations.
The results of the effect of different polymers and surfactants have been
summarized in the table.
Table 4.2 Summary of the Results Obtained for Different Polymers and Surfactants
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4.3.4 Liquid Antisolvent followed by Micros Milling
Another approach for decreasing the particle size even further was tried. The griseofulvin
particles were formed by the liquid antisolvent process and then milled in Micros. 6 g of
griseofulvin was dissolved in 30 ml dichloromethane. The drug solution was pumped at
the rate of 100m1/min into I wt% of HPMC solution placed in a cold bath. The solution
was added in the presence of ultrasonication. The suspension was then immediately
transferred to the micros vessel and milled at 1500 rpm for 75 minutes. The particles size
was measured by LS 230 and SEM micrographs. The plot of the stability of the particles
has been shown below.
- 5 minutes
- 2 hours
- 24 hours
Figure 4.26 Plot of cumulative volume percent versus particle size showing the stability
of particles formed by the liquid antisolvent process followed by milling process.
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Figure 4.27 SEM Micrograph showing the griseofulvin particles obtained by the liquid
antisolvent process follwed by milling.
The particle size was found to be stable over 24 hours. In this process the HPMC
solution was an antisolvent to griseofulvin which caused the precipitation of the drug
particles. HPMC prevented the particles from agglomeration by coating the griseofulvin
particles. This method was more effective since the particles were protected by HPMC as
soon as they were produced by precipitation.
CHAPTER 5
CONCLUSIONS
5.1 Targeted Drug Delivery
5.1.1 Polyelectrolyte Complex Nanoparticles
The process of preparation of the PEC nanoparticles was optimized. The nanoparticles
could be produced in a reproducible manner. The effect of charge ratio, pH, stirring speed
and centrifugation speed on particle size were studied for optimization of the process.
The particle size increased with increase in charge ratio due to the presence of excess
positive charge on the particles promoting the repulsion between the particles, thus
causing a decrease in the particle size. The particle size was found to be fairly constant
between 100-150 nm for charge ratios 15-25. The acidic pH was conducive for the
particle formation process and maintaining the same pH after the separation of particles
was necessary for particle size stabilization. The mixing speed of 2800 rpm was fixed
since it gave the lowest particle size. The PEC NPs were found to be sensitive to high
centrifugation speeds. The particle size increased to 450-500 nm at high speeds and hence
the particles were not suitable for cellular uptake. In addition the number of amine groups
available on the surface of NPs was found to be low indicating the low yield of particles.
Hence they could not be crosslinked and conjugated for drug delivery.
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5.1.2 Albumin Nanoparticles
The albumin nanoparticles were made to overcome the problems of crosslinking,
conjugation and cellular uptake faced in the polyelectrolyte complex nanoparticles. The
albumin nanoparticles were prepared by an already optimized procedure available in the
literature. The amine groups on the surface of NPs were feasible for crosslinking.The
particles size was 117 nm after centrifugation and 230 nm after antibody conjugation. It
thus met the requirements for cellular uptake. The albumin nanoparticles could be
internalized into the cells which was clearly evident from the in-vitro studies.
5.2 Wet Milling
The effect of polymers HPMC, sodium alginate, polymer JR, polyethylene glycol and
polyvinyl pyrolidone on particle size of griseofulvin was studied by milling in Micros.
Sodium alginate and HPMC gave the mean particle size of l.798 and 1.984 gm
respectively since they could wet the griseofulvin particles. None of the other polymers
used, showed any significant effect on particle size reduction. Similarly SDS was found
to be a better surfactant than Pluronic F-68. The use of liquid antisolvent process
followed by milling was found to be the most effective method. The particle size was
l.344 pm and remained stable over 24 hours.
5.3 Future Work
For future work, it is proposed that more detailed in-vivo studies are carried out for the
nanocarriers. The nanocarriers can also be directed to different cell lines by different
antibodies used for conjugation. In addition, it is suggested that the albumin nanoparticles
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are loaded with a drug and studied for the drug release profile. The Griseofulvin size
reduction could be further explored by trying a combination of surfactants and polymers.
In a long-term study, various other APIs should be investigated and final milled size
should be correlated with material properties such as the melting point, crystal strength,
and surface energy. That investigation should also include examination of additives and
the selected APIs should be studied for size reduction, stability, change in morphology
and activity of the API. Also the degree of polymer coating and drug release profile
should be further studied.
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